Exercise of Options and Total Voting Rights

Exercise of Options and Total Voting Rights

Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has issued and allotted 30,000 new ordinary shares of 1 pence each in the capital of the Company (the “New Ordinary Shares”) following an exercise of share options by a former employee.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 28 March 2022 (“Admission”).

Following Admission, the Company will have a total of 60,398,098 Ordinary Shares in issue. Shareholders may use this figure of 60,398,098 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.